Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
The Quick Take
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence - Yahoo Finance Australia
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence Yahoo Finance Australia
Business
GlycoNex Announces Japanese Regulatory Submission for Denosumab Biosimilar SPD8
Regulatory decision in Japan anticipated as early as the end of 2027, subject to PMDA review; GlycoNex continues to seek partners for markets outside Japan NEW…
Business
OceanFirst Financial director Nicos Katsoulis buys $178,277 in stock
Local
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." - CiberCuba
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." CiberCuba